Wedbush Has Bullish Estimate for Prime Medicine Q3 Earnings

Prime Medicine, Inc. (NYSE:PRME - Free Report) - Equities research analysts at Wedbush upped their Q3 2025 earnings per share estimates for Prime Medicine in a report released on Monday, May 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their prior estimate of ($0.41). Wedbush currently has a "Outperform" rating and a $13.00 price target on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share. Wedbush also issued estimates for Prime Medicine's Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.40) EPS, Q1 2026 earnings at ($0.29) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.82) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.89) EPS.

PRME has been the topic of several other research reports. JMP Securities cut their price objective on Prime Medicine from $10.00 to $6.00 and set a "market outperform" rating on the stock in a report on Tuesday, May 20th. HC Wainwright lowered shares of Prime Medicine from a "buy" rating to a "neutral" rating in a report on Tuesday, May 20th. Chardan Capital decreased their price objective on Prime Medicine from $16.00 to $12.00 and set a "buy" rating for the company in a report on Monday, May 19th. Wall Street Zen raised Prime Medicine to a "sell" rating in a report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Prime Medicine in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Prime Medicine has a consensus rating of "Moderate Buy" and a consensus price target of $11.80.

Prime Medicine Stock Up 4.9%

Shares of PRME stock traded up $0.06 on Wednesday, reaching $1.29. The company had a trading volume of 2,003,032 shares, compared to its average volume of 1,328,146. Prime Medicine has a one year low of $1.11 and a one year high of $8.14. The stock has a market capitalization of $169.37 million, a PE ratio of -0.63 and a beta of 1.90. The business's 50-day moving average is $1.52 and its 200 day moving average is $2.42.

Prime Medicine (NYSE:PRME - Get Free Report) last announced its quarterly earnings data on Friday, March 7th. The company reported ($1.65) earnings per share for the quarter. During the same period last year, the company posted ($2.18) earnings per share.

Hedge Funds Weigh In On Prime Medicine

Several institutional investors and hedge funds have recently made changes to their positions in the business. Avanza Fonder AB purchased a new stake in Prime Medicine during the 4th quarter valued at $66,000. Nisa Investment Advisors LLC raised its stake in Prime Medicine by 11,474.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 12,616 shares of the company's stock valued at $37,000 after buying an additional 12,507 shares during the last quarter. SG Americas Securities LLC grew its position in Prime Medicine by 28.2% during the 4th quarter. SG Americas Securities LLC now owns 60,229 shares of the company's stock valued at $176,000 after purchasing an additional 13,247 shares during the last quarter. Impact Partnership Wealth LLC purchased a new position in Prime Medicine in the 4th quarter worth approximately $50,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Prime Medicine by 20.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,811 shares of the company's stock worth $81,000 after buying an additional 4,725 shares during the last quarter. Institutional investors own 70.37% of the company's stock.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.